RESEARCH TRIANGLE PARK, N.C., June 8, 2011 /PRNewswire/ -- (NASDAQ: GRFS) – Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain, today announced that it has officially begun to merge its operations with Talecris Biotherapeutics in order to function as one company, following its acquisition of Talecris on June 1. Through the acquisition, Grifols will build upon its 70-year legacy of creating life-saving medicines and products by incorporating Talecris' substantial experience and skill in producing plasma protein therapies.
"The union of our two companies provides an infusion of energy and talent, and strengthens our commitment to our shared mission of providing life-saving therapies to patients with rare, chronic diseases," said Victor Grifols, President and CEO of Grifols. "The strength of our combined company is not simply its size; rather, it is the potential to achieve more for patients in the future than either company would be able to accomplish on its own."
Combining the respective capabilities of the two companies will allow Grifols to extract more products from each liter of plasma and thus increase the quantity of products and choices available to patients. The company's expanded global footprint will also improve patient access to critical-care protein therapies that are not widely available in many countries.
"The Grifols family has been a leader in producing safe, effective plasma therapies," said John Walsh, president and CEO of the Alpha-1 Foundation. "Under Victor Grifols' leadership we expect that family culture to expand in the United States. The Alpha-1 community has always been a family, and we look forward to a complementary blending of two family traditions."
"Grifols and Talecris have each made significant contributions to the treatment of people with primary immune def